The Story of Antenatal Steroid Therapy before Preterm Birth

Neonatology ◽  
2015 ◽  
Vol 107 (4) ◽  
pp. 352-357 ◽  
Author(s):  
Mikko Hallman
2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
Jason D. Pole ◽  
Cameron A. Mustard ◽  
Teresa To ◽  
Joseph Beyene ◽  
Alexander C. Allen

This study was designed to test the hypothesis that fetal exposure to corticosteroids in the antenatal period is an independent risk factor for the development of asthma in early childhood with little or no effect in later childhood. A population-based cohort study of all pregnant women who resided in Nova Scotia, Canada, and gave birth to a singleton fetus between 1989 and 1998 was undertaken. After a priori specified exclusions, 80,448 infants were available for analysis. Using linked health care utilization records, incident asthma cases developed after 36 months of age were identified. Extended Cox proportional hazards models were used to estimate hazard ratios while controlling for confounders. Exposure to corticosteroids during pregnancy was associated with a risk of asthma in childhood between 3–5 years of age: adjusted hazard ratio of 1.19 (95% confidence interval: 1.03, 1.39), with no association noted after 5 years of age: adjusted hazard ratio for 5–7 years was 1.06 (95% confidence interval: 0.86, 1.30) and for 8 or greater years was 0.74 (95% confidence interval: 0.54, 1.03). Antenatal steroid therapy appears to be an independent risk factor for the development of asthma between 3 and 5 years of age.


Author(s):  
Esra Beser Ozmen ◽  
Gulsum Kadioglu Simsek ◽  
Burak Ceran ◽  
Fuat Emre Canpolat ◽  
H. Gozde Kanmaz Kutman

2014 ◽  
Vol 210 (1) ◽  
pp. S16
Author(s):  
Kathleen Brookfield ◽  
Lisa Chao ◽  
Victoria Berger ◽  
Mariam Naqvi ◽  
Yasser El-Sayed ◽  
...  

2001 ◽  
Vol 31 (6) ◽  
pp. 425-430 ◽  
Author(s):  
Cindy McEvoy ◽  
Susan Bowling ◽  
Kathleen Williamson ◽  
Marion Stewart ◽  
Manuel Durand

2008 ◽  
Vol 70 (5) ◽  
pp. 981-989 ◽  
Author(s):  
Jason D. Pole ◽  
Cameron A. Mustard ◽  
Teresa To ◽  
Joseph Beyene ◽  
Alexander C. Allen

2016 ◽  
Vol 92 (1) ◽  
pp. 24-31
Author(s):  
Joice Fabiola Meneguel Ogata ◽  
Marcelo Cunio Machado Fonseca ◽  
Milton Harumi Miyoshi ◽  
Maria Fernanda Branco de Almeida ◽  
Ruth Guinsburg

Author(s):  
Sebnem Calkavur ◽  
Senem Alkan Özdemir ◽  
Ruya Colak ◽  
Ezgi Yangin Ergon ◽  
Ferit Kulali ◽  
...  

<p><strong>Objective</strong>: We aimed to investigate the role of incomplete  of antenatal steroid therapy by comparing with no and complete steroid exposure on mortality and morbidity in preterm infants.</p><p><strong>Methods:</strong>This is a prospective,observational study which includes preterm infants of 32 weeks of gestation and/or≤1500 grams who were referred to Izmir Dr.Behçet Uz Children's Hospital NICU during the one year period. Infants were divided into three groups according to the administration of antenatal steroid as those who received incomplete-dose antenatal steroid, complete dose steroid therapy  and those with no steroid exposure. Intubation at delivery room, surfactant requirement,the inotropic requirement in the first 72 hours and morbidities associated with prematurity were determined as the primary results. Mortality and bronchopulmonary dysplasia at discharge and stage ≥2 retinopathy were analyzed as secondary outcomes.<strong></strong></p><p><strong>Results:</strong> We found that 54 infants were born with a incomplete dose, 55 infants with complete dose and 38 infants with no steroid therapy. Surfactant requirement, ,intubation requirement,inotropic requirement and hsPDA were lower in the steroid  group leading to a statistical difference (p&lt;0.05).Also it was found that mortality and BPD were lower in the single-dose group,leading to a statistical difference (p&lt;0.05).</p><p><strong><em>Conclusion</em></strong><em>:</em>We speculate that even single-dose steroid may reduce mortality by reducing RDS.</p>


2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Clarissa Velayo ◽  
Takuya Ito ◽  
Yupeng Dong ◽  
Miyuki Endo ◽  
Rika Sugibayashi ◽  
...  

Introduction. Prenatal programming secondary to maternal protein restriction renders an inherent susceptibility to neural compromise in neonates and any addition of glucocorticosteroids results in further damage. This is an investigation of consequent global gene activity due to effects of antenatal steroid therapy on a protein restriction mouse model. Methods. C57BL/6N pregnant mice were administered control or protein restricted diets and subjected to either 100 μg/Kg of dexamethasone sodium phosphate with normosaline or normosaline alone during late gestation (E10–E17). Nontreatment groups were also included. Brain samples were collected on embryonic day 17 and analyzed by mRNA microarray analysis. Results. Microarray analyses presented 332 significantly regulated genes. Overall, neurodevelopmental genes were overrepresented and a subset of 8 genes allowed treatment segregation through the hierarchical clustering method. The addition of stress or steroids greatly affected gene regulation through glucocorticoid receptor and stress signaling pathways. Furthermore, differences between dexamethasone-administered treatments implied a harmful effect during conditions of high stress. Microarray analysis was validated using qPCR. Conclusion. The effects of antenatal steroid therapy vary in fetuses according to maternal-fetal factors and environmental stimuli. Defining the key regulatory networks that signal either beneficial or damaging corticosteroid action would result in valuable adjustments to current treatment protocols.


Sign in / Sign up

Export Citation Format

Share Document